On May 1, 2025 Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), reported that management will participate in two upcoming investor conferences (Press release, Sutro Biopharma, MAY 1, 2025, View Source;utm_medium=rss&utm_campaign=sutro-biopharma-to-participate-in-upcoming-investor-conferences-6 [SID1234652454]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Details:

The Citizens Life Sciences Conference
Date: May 7-8, 2025
Location: New York, NY

BofA Securities 2025 Health Care Conference
Date: May 13-15, 2025
Location: Las Vegas, NV

Webcasts of the presentations will be accessible through the News & Events page of the Investor Relations section of the Company’s website at www.sutrobio.com. Archived replays will be available for at least 30 days after the event.

On May 1, 2025 Repare Therapeutics Inc. ("Repare") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, reported that it has out-licensed its discovery platforms, including certain platform and program intellectual property, to DCx Biotherapeutics Corporation ("DCx"), a newly-launched Canadian biotechnology company developing next generation precision drug conjugates and supported by Amplitude Ventures (Press release, Repare Therapeutics, MAY 1, 2025, View Source [SID1234652453]). Additionally, DCx will retain certain preclinical research personnel, acquire lease rights to certain laboratory facilities in Montreal and acquire certain laboratory equipment.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We have taken careful steps to evaluate all aspects of our business to ensure continued value generation, and this out-licensing agreement with DCx for our discovery platforms enables us to further focus on our clinical portfolio and drive cost reductions while maintaining an economic interest in the platform technologies we have developed." said Steve Forte, President, Chief Executive Officer and Chief Financial Officer of Repare. "We look forward to reporting initial data from our two ongoing Phase 1 clinical trials in the second half of 2025, and continue to evaluate partnering and strategic alternatives across our portfolio assets."

Under the terms of the out-licensing agreement, Repare will receive upfront and near-term payments totaling $4 million, as well as a 9.99% common equity position in DCx (including certain dilution protection rights) and is eligible to receive potential future out-licensing, clinical and commercial milestone payments, as well as low-single digit tiered sales royalites for the development of certain products by DCx. Additionally, DCx will retain approximately 20 of Repare’s preclinical research employees. Repare has the right to appoint one nominee to the board of directors of DCx. In connection with the transaction, Repare out-licensed its clinically-validated SNIPRx platform and its early discovery-stage SNIPRx-surf and STEP2 platforms, along with other intellectual property. The SNIPRx-surf platform identifies cell surface targets based on gene expression and protein features in tumors or cancer models, including by clinically relevant biomarkers and machine learning algorithm. The STEP2 platform is a chemogenomic discovery platform, which uses CRISPR-enabled genetic screens with small molecule inhibitors to identify clinically relevant genetic lesions that are sensitive to small molecule inhibitors.

On May 1, 2025 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported new and updated data from its oncology and hematology portfolio will be shared at the 2025 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place from May 30 to June 3 in Chicago, IL (Press release, Regeneron, MAY 1, 2025, View Source [SID1234652452]). Eighteen presentations will share the latest insights from ongoing research of approved and investigational treatment regimens across a range of difficult-to-treat cancers including non-melanoma and melanoma skin cancer, lung cancer, lymphoma and multiple myeloma.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our broad oncology and hematology programs are uniquely designed to investigate regimens that could provide meaningful impact for people living with difficult-to-treat cancers across all stages of the treatment paradigm," said George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer at Regeneron. "Our PD-1 inhibitor Libtayo is the standard of care in advanced cutaneous squamous cell carcinoma, and in clinical trials, our investigational BCMAxCD3 bispecific antibody linvoseltamab has demonstrated a compelling profile in relapsed or refractory multiple myeloma. At ASCO (Free ASCO Whitepaper), our presentations showcase how we are seeking to further transform the treatment of these diseases with updates from two key programs – our Phase 3 trial exploring adjuvant Libtayo in high-risk cutaneous squamous cell carcinoma and early data from investigational combinations of linvoseltamab and different proteasome inhibitors in third-line or higher multiple myeloma."

Notable presentations at ASCO (Free ASCO Whitepaper) on Regeneron’s oncology pipeline include detailed efficacy and safety findings from the Phase 3 C-POST trial evaluating the adjuvant use of the PD-1 inhibitor Libtayo in post-surgical high-risk cutaneous squamous cell carcinoma (CSCC). The results will be presented in an oral session on Saturday, May 31.

In hematology, Regeneron will debut results from two cohorts of the LINKER-MM2 trial, which is exploring combinations of linvoseltamab, Regeneron’s investigational BCMAxCD3 bispecific antibody. These include combinations of linvoseltamab with carfilzomib or bortezomib in relapsed/refractory (R/R) multiple myeloma (MM) after at least two lines of therapy, which will be featured in two rapid oral presentations on Monday, June 2.

In addition, the results of a cooperative group study reporting on the primary analysis of a randomized Phase 2 trial of vidutolimod in combination with an anti-PD-1 versus anti-PD-1 as neoadjuvant therapy in stage 3 resectable melanoma will be presented in an oral session on Tuesday, June 3. Vidutolimod is a toll like receptor 9 antagonist that was acquired by Regeneron in 2022.

The full list of Regeneron presentations at ASCO (Free ASCO Whitepaper) includes:

Medicine Abstract title Abstract and
Session Lead author Presentation
date/time
(all CDT)
Skin Cancer
Libtayo
Phase 3 trial of
adjuvant cemiplimab
(cemi) versus
placebo (pbo) for
high-risk cutaneous
squamous cell
carcinoma (CSCC) #6001

Oral Abstract
Session – Head
and Neck Cancer Danny Rischin Saturday,
May 31

1:15 p.m. –
4:15 p.m.
Libtayo Patient-reported
outcomes (PROs) in
the C-POST trial of
adjuvant cemiplimab
(cemi) vs placebo
(pbo) for high-risk
cutaneous
squamous cell
carcinoma (CSCC) #6065

Poster Session
– Head and
Neck Cancer Annette M. Lim Monday, June
2

9:00 a.m. –
12:00 p.m.
Libtayo CemiplimAb-rwlc
Survivorship and
Epidemiology
(CASE): Interim
results from a
prospective study of
the safety and
effectiveness of
cemiplimab in
patients with
advanced cutaneous
squamous cell
carcinoma (CSCC)
in a real-world
setting #9533

Poster Session
–
Melanoma/Skin
Cancers Soo J. Park Sunday, June
1

9:00 a.m. –
12:00 p.m.
Libtayo A Phase 3
randomized study of
low-dose
intralesional
cemiplimab versus
primary surgery for
patients with early-
stage cutaneous
squamous cell
carcinoma (CLEAR
CSCC) #TPS9612

Poster Session
–
Melanoma/Skin
Cancers Michael Migden Sunday, June
1

9:00 a.m. –
12:00 p.m.
Fianlimab,
Libtayo A randomized phase
2 peri-operative
(neoadjuvant plus
adjuvant) study of
fianlimab (anti–LAG-
3) plus cemiplimab
(anti–PD-1) versus
anti–PD-1 alone in
patients with
resectable stage III
and IV melanoma #TPS9596

Poster Session
–
Melanoma/Skin
Cancers Rodabe N.
Amaria Sunday, June
1

9:00 a.m. –
12:00 p.m.
Libtayo Utilizing EORTC
Item Library to
develop a tailored
patient-reported
outcome measure
(CSCC-NAAP-32) to
evaluate quality of
life in resectable
advanced (RA)
cutaneous
squamous cell
carcinoma (CSCC) #e18014

Publication-
Only Abstract:
Head and Neck
Cancer Neil Gross N/A
Vidutolimod A phase 2
randomized study of
neoadjuvant
pembrolizumab (P)
alone or in
combination with
vidutolimod (V) in
high-risk resectable
melanoma: ECOG-
ACRIN 6194 #LBA9505

Oral Abstract
Session –
Melanoma/Skin
Cancers Ahmad Tarhini Tuesday, June
3

9:45 a.m. –
12:45 p.m.
Multiple Myeloma
Linvoseltamab Linvoseltamab
(LINVO) +
carfilzomib (CFZ) in
patients (pts) with
relapsed/refractory
multiple myeloma
(RRMM): Initial
results from the
LINKER-MM2 trial #7513

Rapid Oral
Abstract Session –
Hematologic
Malignancies—
Plasma Cell
Dyscrasia Salomon Manier Monday, June
2

8:00 a.m. –
9:30 a.m.
Linvoseltamab Linvoseltamab
(LINVO) +
bortezomib (BTZ) in
patients (pts) with
relapsed/refractory
multiple myeloma
(RRMM): First
results from the
LINKER-MM2 trial #7510

Rapid Oral
Abstract
Session –
Hematologic
Malignancies—
Plasma Cell
Dyscrasia Paula
Rodríguez-Otero Monday, June
2

8:00 a.m. –
9:30 a.m.
Linvoseltamab Indirect comparison
of linvoseltamab
versus elranatamab
for triple-class
exposed (TCE)
relapsed/refractory
multiple myeloma
(RRMM) #7531

Poster Session
– Hematologic
Malignancies—
Plasma Cell
Dyscrasia Sundar
Jagannath Sunday, June
1

9:00 a.m. –
12:00 p.m.
Linvoseltamab Second primary
malignancy (SPM) in
patients (pts) with
multiple myeloma
(MM) receiving
chimeric antigen
receptor T-cell (CAR
T) therapy or other
systemic anticancer
therapy (SACT): A
comparative study
using a real-world
database #7519

Poster Session
– Hematologic
Malignancies—
Plasma Cell
Dyscrasia Attaya
Suvannasankha Sunday, June
1

9:00 a.m. –
12:00 p.m.
Linvoseltamab Concordance
between blinded
independent central
review committee
and physician-
assessed
responses: Analyses
based on a real-
world external
control arm in
relapsed/refractory
multiple myeloma
using International
Myeloma Working
Group data #e19521

Publication-
Only Abstract:
Hematologic
Malignancies—
Plasma Cell
Dyscrasia Brian G. Durie N/A
Lung Cancer
REGN7075,
Libtayo A randomized study
of neoadjuvant
REGN7075 +
cemiplimab +
chemotherapy
(chemo) vs
cemiplimab + chemo
in patients (pts) with
resectable non-small
cell lung cancer
(NSCLC) #TPS8116

Poster Session
–Lung
Cancer—Non-
Small Cell
Local-
Regional/Small
Cell/Other
Thoracic
Cancers Ardy Davarifar Saturday,
May 31

1:30 p.m. –
4:30 p.m.
Fianlimab,
Libtayo Phase 2 peri-
operative study of
fianlimab +
cemiplimab +
chemotherapy
versus cemiplimab +
chemotherapy in
resectable early-
stage non-small cell
lung cancer
(NSCLC) #TPS8117

Poster Session
– Lung Cancer
Non-Small Cell
Local-
Regional/Small
Cell/Other
Thoracic
Cancers Ekaterine
Arkania Saturday,
May 31

1:30 p.m. –
4:30 p.m.
Libtayo Evaluation of current
programmed death-
ligand 1 (PD-L1)
testing trends for
metastatic non-small
cell lung cancer
(mNSCLC): Insights
from a large network
of US community
oncology practices #e23294

Publication-
Only Abstract:
Quality
Care/Health
Services
Research Kathleen M.
Aguilar N/A
Libtayo Evaluating the
safety and
effectiveness of
cemiplimab in
combination with
platinum-doublet
chemotherapy by
demographic
characteristics in
first-line treatment of
advanced non-small
cell lung cancer: An
ongoing multi-
database real world
evidence study in
US patients #e20572

Publication-
Only Abstract:
Lung Cancer—
Non-Small Cell
Metastatic Alexi
Archambault N/A
Head and Neck Cancer
Fianlimab,
Libtayo A Phase 2 study of
fianlimab (anti-LAG-
3) plus cemiplimab
(anti-PD-1) versus
cemiplimab plus
placebo in patients
with
recurrent/metastatic
head and neck
squamous cell
carcinoma (HNSCC)
with positive PD-L1
expression #TPS6112

Poster Session
– Head and
Neck Cancer Danny Rischin Monday, June
2

9:00 a.m. –
12:00 p.m.
Lymphoma
Odronextamab Long-term follow-up
of the phase 2 ELM-
2 study:
Odronextamab for
patients (pts) with
relapsed/refractory
(R/R) follicular
lymphoma (FL) #7049

Poster Session –
Hematologic
Malignancies—
Lymphoma and
Chronic
Lymphocytic
Leukemia Deepa
Jagadeesh Sunday, June
1

9:00 a.m. –
12:00 p.m.
Odronextamab Second primary
malignancy in
patients with diffuse
large B-cell
lymphoma (DLBCL)
receiving chimeric
antigen receptor T-
cell (CAR T) therapy
and other systemic
anti-cancer therapy:
A real-world data
analysis #7080

Poster Session
– Hematologic
Malignancies—
Lymphoma and
Chronic
Lymphocytic
Leukemia Matthew
Lunning Sunday, June
1

9:00 a.m. –
12:00 p.m.

The potential uses of Libtayo in adjuvant CSCC, fianlimab, REGN7075, vidutolimod, and the combinations with linvoseltamab described above are investigational, and their safety and efficacy in these uses have not been fully evaluated by any regulatory authority. Fianlimab, REGN7075 and vidutolimod are not currently approved for use in any indication. Odronextamab is conditionally approved as Ordspono in the European Union for the treatment of R/R follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy, although its safety and efficacy have not been fully evaluated by any other regulatory authority. Linvoseltamab is conditionally approved as Lynozyfic in the European Union for the treatment of adult patients with R/R multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy, although its safety and efficacy have not been fully evaluated by any other regulatory authority. The U.S. Food and Drug Administration (FDA) accepted for review the Biologics License Applications for linvoseltamab and odronextamab with respective target action dates for FDA decisions of July 10, 2025 and July 30, 2025.

On May 1, 2025 Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, reported that five abstracts detailing Precision’s wholly owned or partnered programs have been accepted for presentation at the American Society of Gene and Cell Therapy (ASGCT) (Free ASGCT Whitepaper) Annual Meeting being held May 13-17, 2025, in New Orleans, Louisiana (Press release, Precision Biosciences, MAY 1, 2025, View Source [SID1234652451]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to present new data at ASGCT (Free ASGCT Whitepaper) from multiple programs across our in vivo gene editing pipeline, highlighting the potentially unmatched breadth and therapeutic potential of our ARCUS gene editing technology," said Michael Amoroso, President and Chief Executive Officer at Precision BioSciences. "Clinically, we have made progress advancing our lead program, PBGENE-HBV, which is a novel gene editing approach being evaluated in a first-in-human study for chronic hepatitis B, and we look forward to sharing initial safety data from the first two dose cohorts at ASGCT (Free ASGCT Whitepaper). Additionally, we continue to be excited by the promising clinical results generated thus far by our partner iECURE for ECUR-506 in OTC deficiency, which utilizes an ARCUS nuclease and will also be presenting data at this conference."

"We are also excited to share promising preclinical results from two muscle programs, PBGENE-3243 program for m.3243-associated mitochondrial disease and PBGENE-DMD for the treatment of Duchenne Muscular Dystrophy (DMD)," Mr. Amoroso continued. "Collectively, these presentations highlight the progress we are making with ARCUS by deploying a variety of gene edit types, including gene elimination, gene insertion and gene excision across a range of complex genetic diseases as we seek to develop durable, curative treatments for patients."

Clinical Program Presentations:

Title: Initial Safety Data From ELIMINATE-B, the First Clinical Trial of a Gene Editing Treatment for Chronic Hepatitis B
Oral Presentation Session: Gene Therapy Trials – In-Vivo Gene Therapy Modification
Date and Time: Friday, May 16, 2025, 4:00 PM CT
Location: Room 393-396

Title: ARCUS in vivo OTC, Large Gene Insertion (clinical stage partnered program)
Oral Presentation Session: Advances in Genome Editing: Novel Large DNA Insertion Technologies and Their Potential Towards Curative Therapies
Date and Time: Wednesday, May 14, 2025, 8:00 AM CT
Location: NOLA Theater B

Preclinical Program Presentations:

Title: Excision of the C9orf72 Hexanucleotide Repeat Expansion Using a Dual-ARCUS Gene Editing Approach Reduces Neurotoxic RNA Foci and Dipeptides in an In Vivo Model of ALS
Poster Session: Poster Reception
Date and Time: Tuesday, May 13, 2025, 6:00 PM – 7:30 PM CT
Location: Poster Hall I2

Title: Systemic Delivery of a Mitochondria-Targeting ARCUS Gene Editing Nuclease by AAV Eliminates Mutant Mitochondrial DNA, Demonstrating Therapeutically Meaningful Heteroplasmy Shifts In Vivo
Oral Presentation Session: Gene Editing: New Tools and Technology Advances
Date and Time: Wednesday, May 14, 2025, 3:45 PM CT
Location: NOLA Theater A

Title: ARCUS-Mediated Gene Editing Excision of Exons 45-55 of the Human Dystrophin Gene using PBGENE-DMD Leads to Functional Dystrophin Protein and Durable Restoration of Skeletal Muscle-Function In Vivo for the Treatment of Duchenne Muscular Dystrophy
Poster Session: Poster Reception
Date and Time: Wednesday, May 14, 2025, 5:30 PM – 7:00 PM CT
Location: Poster Hall I2

The abstracts are now publicly accessible through the ASGCT (Free ASGCT Whitepaper) website here.

On May 1, 2025 NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, reported a business update and provided first quarter 2025 financial results (Press release, NextCure, MAY 1, 2025, View Source [SID1234652450]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"With our LNCB74 antibody-drug conjugate ("ADC") program completing cohort 2 in April 2025, we are progressing as planned through the dose escalation portion of the Phase 1 study. We expect to be in a position to initiate backfill cohorts in the second half of the year with 10 active investigator sites, and an additional 3 sites projected to be onboard in May 2025. We plan to provide a proof of concept data readout in the first half of 2026," said Michael Richman, NextCure’s president and CEO.

Business Highlights and Near-Term Milestones

LNCB74 (B7-H4 ADC)

● Dosed our first patient in January 2025 in the Phase 1 trial, cleared cohort 2 in April 2025 and currently dosing cohort 3.
● Expanded clinical footprint for the LNCB74 study with a total of 10 active trial sites.
● Plan to initiate backfill cohorts in the second half of 2025.
● Plan to provide a proof of concept data readout in the first half of 2026.

Preclinical Non-Oncology Programs Seeking Partnering

● Preclinical data for NC181 (ApoE4), a humanized antibody for the treatment of Alzheimer’s disease, has demonstrated amyloid clearance, prevention of amyloid deposition, plaque clearance and reduced neuroinflammation.
● Preclinical data for NC605 (Siglec-15), a humanized antibody for the treatment of osteogenesis Imperfecta (OI), has demonstrated that NC605 treatment reduced bone loss and enhanced bone quality in mice with OI.
● Both programs could lead to investigational new drug (IND) filings within 12 to 18 months if financial support from partners or third parties is secured.

Financial Results for Quarter Ended March 31, 2025

● Cash, cash equivalents, and marketable securities as of March 31, 2025 were $55.9 million as compared to $68.6 million as of December 31, 2024. The decrease of $12.8 million was primarily due to cash used to fund operations. We expect current financial resources to be sufficient to fund operating expenses and capital expenditures into the second half of 2026.
● Research and development expenses were $7.9 million for the three months ended March 31, 2025, as compared to $11.4 million for the three months ended March 31, 2024. The decrease of $3.5 million was due to lower costs related to programs other than LNCB74, lower preclinical development costs and lower personnel-related costs resulting from the restructuring and reduction-in-force announced during the first quarter of 2024 (the "2024 Restructuring").
● General and administrative expenses were $3.7 million for the three months ended March 31, 2025, as compared to $4.4 million for the three months ended March 31, 2024. The decrease of $0.6 million was primarily related to lower personnel costs and lower insurance costs resulting from the 2024 Restructuring.
● There were no restructuring and asset impairment costs for the three months ended March 31, 2025 as compared to $2.5 million for the three months ended March 31, 2024, which costs resulted from the 2024 Restructuring.
● Net loss was $11.0 million for the three months ended March 31, 2025, as compared to a net loss of $17.1 million for the three months ended March 31, 2024 due to lower costs as described above.